Rilpivirine Arrives — with Caveats

For now, the single-pill regimen of tenofovir/FTC/rilpivirine should probably be reserved for use in selected patients.

In 2011, we saw the approval of the nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine both alone and, more important, in a one-pill, once-daily regimen with tenofovir/FTC (JW AIDS Clin Care May 27 2011 and Aug 15 2011). The approval of the coformulated regimen (Complera) prompted the U.S. Department of Health and Human Services to issue an interim guideline update (JW AIDS Clin Care Sep 12 2011), listing tenofovir/FTC/rilpivirine as an alternative (rather than a preferred) regimen.

The guideline panel's assessment was based on the results of two large, pivotal trials comparing rilpivirine to efavirenz, each in combination with two nucleosides (80% tenofovir/FTC; JW AIDS Clin Care Aug 1 2011). In both trials, rilpivirine and e…

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Rilpivirine Arrives — with Caveats

Topics

Author